AOD-9604

People run it for fat loss — specifically the promise of burning fat without raising growth hormone, IGF-1, or touching blood sugar. The community use is a daily fasted shot as a lean-out adjunct alongside diet and training. Worth saying plainly up front: the human obesity trials that tested exactly this largely failed to outperform placebo, so what people are buying is a mechanism story, not a results story.

The whole idea is selectivity by subtraction. Full-length growth hormone raises IGF-1, can worsen insulin sensitivity, and carries the GH side-effect load — AOD-9604 is just residues 176–191 from the C-terminal tail (with a tyrosine tacked on for stability), the slice where GH’s fat-burning activity was thought to live. In animals it raised fat oxidation and trimmed weight without the GH/IGF-1 effects, which is a genuinely elegant result. The catch is that elegant-in-mice didn’t carry to humans, and that gap is the entire honest story of this peptide.

It’s a fragment of the C-terminal lipolytic region of human growth hormone, engineered to keep the fat-mobilizing activity while losing the receptor binding that raises IGF-1 and disturbs glucose. In obese mice it stimulated lipolysis (fat breakdown), suppressed lipogenesis (new fat storage), and increased fat oxidation — and the proposed link is the β3-adrenergic pathway: it restored suppressed β3-adrenergic-receptor expression in obese mice toward lean levels. Notably, even in the animal work the lipolytic effect wasn’t mediated directly through the β3 receptor — in β3-knockout mice the weight and lipolysis effects disappeared, so the receptor is necessary but the mechanism is indirect and not fully pinned down. None of this should be read as confirmed in humans.

This is the one area where AOD-9604 genuinely delivers: across the human trials it was very well tolerated, with a side-effect profile reported as essentially indistinguishable from placebo. It had no effect on serum IGF-1 and no negative effect on carbohydrate metabolism — the clean part of the pitch is real. The blunt caveat is that an excellent safety record on a compound that didn’t beat placebo for its main use is faint praise: it’s safe partly because it doesn’t do very much. As always in this space, the market is unregulated — insist on a certificate of analysis before running anything.

There’s no evidence-based stack. In community use people fold it into fat-loss routines — fasted training, sometimes alongside a GH secretagogue stack (CJC-1295/Ipamorelin) on the theory that AOD handles lipolysis while the secretagogues handle GH — but none of that pairing rests on human data, and AOD-9604’s own efficacy data are negative to begin with. The honest version: it’s run as a hopeful add-on to diet and training, not as a load-bearing part of any protocol.